Next, to investigate how the combination of a STING agonist and anti-TIM-1 antibody reprograms the immune TME of HCC, we conducted a time-matched cohort study using the HCA-1 model in mice with liver damage. Here, STING1 is linked to hepatocellular carcinoma.